Durvalamab (Imfinzi®) is a Health Canada approved immunotherapy that is currently used in the treatment of lung cancer, but is similar to another drug called Atezolizumab (Tecentriq®) which is already approved for the treatment of Kidney Cancer in Canada. These drugs work by targeting a molecule called PD-L1 which enables the immune system to more effectively recognize and destroy cancer cells.
Sunitinib (Sutent®) has been a Health Canada approved treatment for kidney cancer since 2006. This drug belongs to a family of therapies known as “tyrosine kinase inhibitors” and works by blocking a molecule called VEGFR to prevent cancerous tumours from growing new blood vessels and obtaining the nutrients they need to grow.
Savolitinib (Orpathys®) is an experimental cancer treatment that also belongs to the “tyrosine kinase inhibitors” family. This medication is similar to Cabozantinib (Cabometyx®), an already-approved treatment for advanced kidney cancer. Savolitinib works by blocking a molecule called c-MET which prevents susceptible cancer cells from growing and dividing.
This study will have three treatment groups that will be randomly assigned upon your enrollment in the trial:
Group 1: Savolitinib + Durvalamab
Group 2: Durvalamab alone
Group 3: Sunitinib alone
There is no control group in the study, so there will be no “placebo”, and all patients will receive some form of treatment.
- Papillary kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- Genetic test required to confirm c-MET is involved in driving your cancer
- No prior treatment is allowed with any of the study drugs, or any other c-MET inhibitor (e.g. Cabozantinib)
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreTom Baker Cancer Centre||Principal InvestigatorNot Given||LocationCalgary, AB||Trial StatusRecruiting|
|Hospital / Cancer CentreSegal Cancer Centre - Jewish General Hospital||Principal InvestigatorNot Given||LocationMontreal, QB||Trial StatusRecruiting|